A Title Earned, Not Given

There is a phrase that gets used often in conversations about global health, sometimes so casually that its weight is easy to miss: "the pharmacy of the world." It is not a slogan invented by a marketing department or a government press release. It is a description that has been earned, quietly and steadily, over decades, by an Indian pharmaceutical industry that today manufactures medicines reaching more than 200 countries, supplies roughly three in every five vaccine doses used anywhere on Earth, and produces one in every five generic pills swallowed by patients worldwide.To understand how India arrived at this position — and why it matters so profoundly for global health security — is to understand a story that begins not with a single dramatic breakthrough, but with decades of patient investment in manufacturing capability, scientific talent, and regulatory credibility.

The Foundations: Building an Industry From Scratch

India's pharmaceutical story did not begin with abundance. In the decades after independence, the country was heavily dependent on imported medicines, many of them priced far beyond the reach of ordinary citizens. The turning point came with a series of policy decisions in the 1970s that reformed India's patent laws to allow domestic companies to manufacture process-based generic versions of medicines, rather than being locked out by product patents held by multinational firms. This single legislative shift, controversial at the time, planted the seed for what would become one of the most consequential pharmaceutical ecosystems in the worldFreed to develop their own manufacturing processes, Indian companies built expertise in reverse-engineering complex drug molecules and producing them at a fraction of the cost charged by the original patent holders. Over the following decades, this expertise matured into something far more sophisticated: an industry of more than 3,000 pharmaceutical companies and over 10,500 manufacturing units, many of them certified to the exacting standards of the US Food and Drug Administration, the European Medicines Agency, and the World Health Organization. India today hosts more USFDA-approved manufacturing facilities than any country outside the United States itself — a testament to a quality culture built over generations rather than achieved overnight.By the mid-2020s, this ecosystem had grown into a domestic pharmaceutical market valued at roughly 60 billion dollars, with government and industry projections suggesting it could climb toward 130 billion dollars by the end of the decade, and toward an ambitious 450 billion dollar target by the time India marks a century of independence in 2047.

Medicines for the Many: The Generics Revolution

Perhaps India's single greatest contribution to global health has been making effective medicine affordable for people who would otherwise never have been able to access it. Indian manufacturers today account for roughly one-fifth of the world's generic medicine supply by volume, producing an estimated 60,000 generic drug brands across some 60 therapeutic categories. Put simply, when a patient anywhere in the developing world — and increasingly in wealthier nations too — takes a low-cost version of a life-saving medicine, there is a strong chance it was manufactured in a factory in Gujarat, Telangana, Himachal Pradesh, or one of India's other pharmaceutical manufacturing hubs.Nowhere has this been more consequential than in the fight against HIV/AIDS. At the height of the global AIDS crisis in the early 2000s, antiretroviral therapy cost thousands of dollars per patient per year in the West, placing it entirely out of reach for the millions of people living with HIV across sub-Saharan Africa and other low-income regions. Indian generic manufacturers changed that equation dramatically, driving down the cost of antiretroviral treatment to a fraction of its original price. Today, Indian companies continue to supply more than 80 percent of the antiretroviral medicines used to treat HIV/AIDS patients across the globe — a single statistic that, on its own, represents millions of lives extended and protected.This pattern — taking a life-saving therapy and making it accessible at scale — has repeated itself across tuberculosis treatment, malaria medication, and a wide range of essential medicines that international health bodies rely upon to serve the world's most vulnerable populations.

The Vaccine Powerhouse

If generics represent India's contribution to treating disease, vaccines represent its contribution to preventing it altogether — and it is here that India's global role becomes perhaps most striking. India is, by volume, the largest vaccine manufacturer on the planet, responsible for producing roughly 60 percent of all vaccine doses manufactured worldwide. Institutions such as the Serum Institute of India, the world's largest vaccine manufacturer by number of doses produced, have made India's vaccine ecosystem a genuine cornerstone of global immunisation efforts.The scale of India's contribution to global vaccine bodies is difficult to overstate. Indian manufacturers supply an estimated 55 to 60 percent of all vaccines procured by UNICEF for distribution to children across the developing world. India meets close to the entirety of the World Health Organization's global demand for diphtheria-pertussis-tetanus (DPT) vaccines, alongside a majority share of the world's BCG tuberculosis vaccine supply and a substantial portion of global measles vaccine demand. According to some estimates, Indian-made vaccines fulfil somewhere between 65 and 70 percent of the WHO's overall vaccine procurement needs. Behind these percentages lies a simple, powerful reality: because Indian manufacturers have driven down the cost of vaccine production while maintaining the quality standards required for WHO prequalification, national immunisation programmes in dozens of low- and middle-income countries have been able to vaccinate children against deadly, preventable diseases at a scale that would otherwise have been financially impossible.

The COVID-19 Test — And India's Response

If there was ever a moment that put India's pharmaceutical capacity to a truly global test, it was the COVID-19 pandemic. As the world scrambled for vaccine doses in late 2020 and early 2021, India's manufacturing base — already the largest in the world by volume — was rapidly mobilised to produce and distribute vaccines not only domestically but internationally. Under what came to be known as India's vaccine diplomacy, the country began shipping doses to neighbouring nations within days of finalising its own vaccination framework, with early consignments reaching countries such as Bhutan as part of a broader effort to support immunisation campaigns across South Asia, Africa, and Latin America. Over the following months and years, India supplied COVID-19 vaccines to well over 200 countries, at a time when vaccine nationalism in wealthier nations had left many lower-income countries struggling to secure doses at all.The pandemic left a lasting legacy beyond the immediate crisis it addressed. Much of the manufacturing capacity that India built or expanded to meet COVID-19 vaccine demand has since been repurposed toward routine immunisation efforts worldwide, and India's vaccine exports — which stood at close to nothing barely half a decade ago — climbed to well over a billion dollars in value within a few years, reflecting a permanent expansion of the country's role as a supplier of preventive healthcare to the world.

Earning Global Trust: Quality Over Cheap Labels

For years, sceptics dismissed low-cost Indian medicines as a trade-off between affordability and quality. That perception has changed substantially, and deliberately so. India's drug regulatory framework, anchored by the Central Drugs Standard Control Organisation and the Indian Pharmacopoeia Commission, has steadily aligned itself with international benchmarks, and the standards set by the Indian Pharmacopoeia are now recognised in nineteen countries. More tellingly, the fact that Indian factories host the largest number of USFDA-approved manufacturing sites outside the United States itself is not something that can be achieved through cost-cutting alone; it requires sustained investment in quality systems, documentation, staff training, and repeated regulatory inspection.This credibility has allowed Indian pharmaceutical companies to move beyond their traditional reputation as low-cost copycat manufacturers and into more sophisticated territory: complex generics, injectable formulations, biosimilars, and increasingly, original research. Several Indian firms now run substantial research and development operations aimed not just at replicating existing molecules but at developing new formulations, drug delivery systems, and, in a growing number of cases, entirely novel therapies. The government's push toward biologics and biosimilars through initiatives like Biopharma SHAKTI reflects a broader ambition: for India to be known not only as the world's manufacturing floor for medicine, but increasingly as a genuine centre of pharmaceutical innovation as well.

Reaching Every Corner of the Globe

The scale of India's pharmaceutical export footprint bears repeating in concrete terms. In the 2024-25 financial year alone, India's exports of drugs and pharmaceuticals reached roughly 30.5 billion dollars, nearly sixteen times the value recorded just two and a half decades earlier. These exports reached patients and health systems in 191 to over 200 countries, according to various government and industry estimates, with roughly half directed toward the world's most tightly regulated markets, including the United States and the European Union — a strong signal of the trust that global regulators and healthcare systems place in Indian-manufactured medicines.This growth has not been confined to traditional generic tablets and capsules. India's medical technology exports, including diagnostic equipment and devices, rose to over 4 billion dollars in the same period, while newer segments such as biosimilars, complex generics, and specialty formulations have posted some of the fastest growth rates within the industry. The government's proposed Biopharma SHAKTI initiative, backed by a outlay in the range of 10,000 crore rupees, aims to push India further up the value chain, from a country known primarily for manufacturing scale toward one increasingly recognised for biologics innovation as well.

At home, this affordability mission has taken a particularly tangible form through the Jan Aushadhi Kendra scheme, a network of government-supported pharmacy outlets that by early 2026 had grown to more than 18,000 stores across the country, offering quality generic medicines at prices low enough to save Indian citizens an estimated 8,000 crore rupees annually — a reminder that the same manufacturing capability powering global health also serves India's own citizens first.

Why This Matters Beyond Economics

It would be easy to tell this story purely in terms of export figures and market share, but that would miss its deeper significance. Global health security depends fundamentally on the world having enough manufacturing capacity, spread across enough geographies, to respond when disease outbreaks strike or when routine immunisation needs must be met at massive scale. A world dependent on a small handful of high-cost manufacturers is a world more vulnerable to supply shocks, price spikes, and the kind of vaccine nationalism that left so many countries stranded during the darkest days of the pandemic.

India's emergence as a large, reliable, quality-certified manufacturing base has functioned as a kind of insurance policy for global public health — one that has already been tested and proven during real crises. For international health bodies like the WHO and UNICEF, working with Indian suppliers is not an act of charity but a matter of practical necessity: without India's capacity, immunisation targets that currently protect hundreds of millions of children each year would simply be unachievable at any comparable cost.

Looking Ahead

India's own ambitions for this sector continue to grow. Industry and government projections point toward pharmaceutical export opportunities reaching as high as 100 billion dollars by 2030, driven by continued growth in vaccines, biosimilars, and specialty generics, alongside newly concluded and proposed trade agreements with the European Union, the United Kingdom, and other partners that promise easier market access for Indian medicines and devices. Investments through schemes like the Production Linked Incentive programme are also working to reduce India's own historical dependence on imported raw pharmaceutical ingredients, strengthening the resilience of the very supply chains the rest of the world has come to rely upon.
What began as a domestic effort to make medicine affordable for Indian citizens has, across five decades, become one of the quieter but more consequential Indian contributions to human welfare anywhere on the globe. Every child immunised with a low-cost vaccine manufactured in Pune, every HIV patient in sub-Saharan Africa able to afford daily antiretroviral therapy, every hospital in a lower-income country able to stock essential medicines within its budget — each represents a small thread in a much larger story: a story of a nation that chose, deliberately and over generations, to build the capability to keep the world a little healthier, and a little safer.